Overview

Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer

Status:
Unknown status

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

In this study, patients with adenocarcinoma of the stomach, gastro-esophageal junction or the distal esophagus who seem operable with curative intent according to oncological and surgical assessment are treated with 3 preoperative cycles of DCX (Docetaxel, Cisplatin, Capecitabine) followed by surgical resection, followed by 3 postoperative cycles of DCX.

Phase:

Phase 2

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborators:

Roche Pharma AG
Sanofi

Treatments:

Capecitabine
Cisplatin
Docetaxel